Review: Limited evidence suggests that statins are safe in patients with liver disease: Commentary

Evidence-Based Medicine

Volumn 13, Issue 5, 2008, Pages 140-

  Bates, Eric R ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FENOFIBRATE; GEMCITABINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OCTREOTIDE; PLACEBO; URSODEOXYCHOLIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FUNCTION TEST; LIVER TOXICITY; LIVER TRANSPLANTATION; MEDLINE; MYOSITIS; NONALCOHOLIC FATTY LIVER; RHABDOMYOLYSIS; SHORT SURVEY; SIDE EFFECT; SURVIVAL RATE;

EID: 55049113048     PISSN: 13565524     EISSN: None     Source Type: Journal    
DOI: 10.1136/ebm.13.5.140     Document Type: Short Survey

References (1)

1. Mckenney JM, Davidson MH, Jacobson TA, et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006;97:89-94C.